Differences in the association of PAI-1 activity with the metabolic syndrome between African and Caucasian women

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 7, 2007, Pages 499-507

  Greyling, A ^a   Pieters, M ^a   Hoekstra, T ^a   Oosthuizen, W ^a   Schutte, A E ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Insulin resistance; Metabolic syndrome; Obesity; PAI 1

Indexed keywords

BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ABDOMINAL FAT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; BODY MASS; CAUCASIAN; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; ETHNOLOGY; FEMALE; HUMAN; METABOLIC SYNDROME X; METABOLISM; NEGRO; RISK FACTOR; WAIST HIP RATIO;

ABDOMINAL FAT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; METABOLIC SYNDROME X; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; WAIST-HIP RATIO;

EID: 34547426864     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2006.04.006     Document Type: Article

References (49)

1. Bradshaw D., Schneider M., Dorrington R., Bourne D.E., and Laubscher R. South African cause-of-death profile in transition-1996 and future trends. S Afr Med J 92 (2002) 618-623
2. Vorster H.H. The emergence of cardiovascular disease during urbanisation of Africans. Public Health Nutr 5 (2002) 239-243
3. Yusuf S., Reddy S., Ounpuu S., and Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104 (2001) 2746-2753
4. Seftal H.C., Raal F.J., and Joffe B.I. Dyslipidaemia in South Africa. Chronic disease of lifestyle in South Africa. MRC Technical Report (1995), Medical Research Council, Cape Town p. 61-71
5. Steyn K., Sliwa K., Hawken S., Commerford P., Onen C., Damasceno A., et al. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation 112 (2005) 3554-3561
6. Reaven G.M. Hemostatic abnormalities associated with obesity and the metabolic syndrome. J Thromb Haemost 3 (2005) 1074-1075
7. Juhan-Vague I., Alessi M.C., Mavri A., and Morange P.E. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1 (2003) 1575-1579
8. Mertens I., Verrijken A., Michiels J.J., Van der P.M., Ruige J.B., and Van Gaal L.F. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) (2006) [E-pub, ahead of print]
9. Mertens I., and Van Gaal L.F. Obesity, haemostasis and the fibrinolytic system. Obes Rev 3 (2002) 85-101
10. Poirier P., Giles T.D., Bray G.A., Hong Y., Stern J.S., Pi-Sunyer F.X., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113 (2006) 898-918
11. Festa A., D'Agostino Jr. R., Rich S.S., Jenny N.S., Tracy R.P., and Haffner S.M. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 107 (2003) 2422-2427
12. Jerling J.C., Vorster H.H., Oosthuizen W., Silvis N., and Venter C.S. Differences in plasminogen activator inhibitor 1 activity between blacks and whites may be diet related. Haemostasis 24 (1994) 364-368
13. WHO/FAO Expert Consultation. Obesity, Preventing and Managing the Global Epidemic. WHO technical support series (1997), World Health Organization, Geneva
14. Schutte A.E., Kruger H.S., Wissing M.P., Underhay C., and Vorster H.H. The emergence of the metabolic syndrome in urban obese African women: The POWIRS-Study. S Afr J Sci 101 (2005) 61-67
15. WHO/FAO Expert Consultation. Non-communicable disease surveillance. WHO technical support series (2005), World Health Organization, Geneva
16. MacIntyre U.E. Dietary intakes of Africans in transition in the North West Province. PhD thesis (1998), North-West University, Potchefstroom
17. Norton K., and Olds T. Anthropometrica. A textbook of body measurement for sports and health courses (1996), University of New South Wales Press, Sydney p. 30-65
18. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
19. Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 17 (1957) 237-246
20. Neeley W.E. Simple automated determination of serum or plasma glucose by a hexokinase-glucose-6-phosphate dehydrogenase method. Clin Chem 18 (1972) 509-515
21. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
22. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement: executive summary. Circulation 112 (2005) e285-e290
23. Cohen J. Statistical power analysis for the behavioral sciences. Revised ed. (1977), Lawrence Erlbaum Associates, Inc., Hillsdale p. 474
24. Snedecor G.W., and Cochran W.G. Statistical methods (1982), Iowa State University Press, Iowa p. 507
25. Agyemang C., Bindraban N., Mairuhu G., Montfrans G., Koopmans R., and Stronks K. Prevalence, awareness, treatment, and control of hypertension among Black Surinamese, South Asian Surinamese and White Dutch in Amsterdam, The Netherlands: the SUNSET study. J Hypertens 23 (2005) 1971-1977
26. Budoff M.J., Nasir K., Mao S., Tseng P.H., Chau A., Liu S.T., et al. Ethnic differences of the presence and severity of coronary atherosclerosis. Atherosclerosis (2005) [E-pub, ahead of print]
27. Tittelbach T.J., Berman D.M., Nicklas B.J., Ryan A.S., and Goldberg A.P. Racial differences in adipocyte size and relationship to the metabolic syndrome in obese women. Obes Res 12 (2004) 990-998
28. Despres J.P., Couillard C., Gagnon J., Bergeron J., Leon A.S., Rao D.C., et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol 20 (2000) 1932-1938
29. Folsom A.R., Wu K.K., Conlan M.G., Finch A., Davis C.E., Marcucci G., et al. Distributions of hemostatic variables in blacks and whites: population reference values from the Atherosclerosis Risk in Communities (ARIC) Study. Ethn Dis 2 (1992) 35-46
30. Margaglione M., Cappucci G., d'Addedda M., Colaizzo D., Giuliani N., Vecchione G., et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 18 (1998) 562-567
31. Nakamura T., Adachi H., Hirai Y., Satoh A., Ohuchida M., and Imaizumi T. Association of plasminogen activator inhibitor-1 with insulin resistance in Japan where obesity is rare. Metabolism 52 (2003) 226-229
32. Sartori M.T., Vettor R., De Pergola G., De Mitrio V., Saggiorato G., Della Mea P., et al. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance. Thromb Haemost 86 (2001) 1161-1169
33. Sasaki A., Kurisu A., Ohno M., and Ikeda Y. Overweight/obesity, smoking, and heavy alcohol consumption are important determinants of plasma PAI-1 levels in healthy men. Am J Med Sci 322 (2001) 19-23
34. Scarabin P.Y., Aillaud M.F., Amouyel P., Evans A., Luc G., Ferrieres J., et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction-the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 80 (1998) 749-756
35. Solano M.P., Perry A.C., Wang X., Ross R., and Goldberg R.B. Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women. Int J Obes Relat Metab Disord 27 (2003) 82-87
36. Yarnell J.W., Sweetnam P.M., Rumley A., and Lowe G.D. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study. Arterioscler Thromb Vasc Biol 20 (2000) 271-279
37. Alessi M.C., Peiretti F., Morange P., Henry M., Nalbone G., and Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46 (1997) 860-867
38. Alessi M.C., Bastelica D., Morange P., Berthet B., Leduc I., Verdier M., et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 49 (2000) 1374-1380
39. Samad F., Yamamoto K., and Loskutoff D.J. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 97 (1996) 37-46
40. Bastelica D., Morange P., Berthet B., Borghi H., Lacroix O., Grino M., et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 22 (2002) 173-178
41. Cigolini M., Tonoli M., Borgato L., Frigotto L., Manzato F., Zeminian S., et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?. Atherosclerosis 143 (1999) 81-90
42. Conway J.M., Yanovski S.Z., Avila N.A., and Hubbard V.S. Visceral adipose tissue differences in black and white women. Am J Clin Nutr 61 (1995) 765-771
43. Krebs M., Geiger M., Polak K., Vales A., Schmetterer L., Wagner O.F., et al. Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man. Thromb Haemost 90 (2003) 422-428
44. Dawson S., Hamsten A., Wiman B., Henney A., and Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11 (1991) 183-190
45. Eriksson P., Kallin B., 't Hooft F.M., Bavenholm P., and Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92 (1995) 1851-1855
46. Panahloo A., Mohamed-Ali V., Lane A., Green F., Humphries S.E., and Yudkin J.S. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 44 (1995) 37-42
47. Ye S., Green F.R., Scarabin P.Y., Nicaud V., Bara L., Dawson S.J., et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost 74 (1995) 837-841
48. Crainich P., Jenny N.S., Tang Z., Arnold A.M., Kuller L.H., Manolio T., et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost 1 (2003) 1799-1804
49. Pegoraro R.J., Hira B., Rom L., and Moodley J. Plasminogen activator inhibitor type 1 (PAI1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in Black South Africans with pre-eclampsia. Acta Obstet Gynecol Scand 82 (2003) 313-317